Macrocyclic egfr inhibitors for the treatment of cancer
AssigneeTheseus Pharmaceuticals, Inc.
InventorsWei-Sheng HUANG, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
Life of this patent
Estimating the term…
Loading patent…
AssigneeTheseus Pharmaceuticals, Inc.
InventorsWei-Sheng HUANG, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
Estimating the term…
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
A compound of Formula I:
Dependencies are inferred from the claim text.